Texas Standard Prior Authorization Form Addendum

Molina Healthcare of Texas

Cytokine and CAM Antagonists – Enbrel (etanercept) (Medicaid)

This fax machine is located in a secure location as required by HIPAA Regulations. Complete / Review information, sign, and date. Fax signed forms to Molina Pharmacy Prior Authorization Department at **1-888-487-9251**. Please contact Molina Pharmacy Prior Authorization Department at **1-855-322-4080** with questions regarding the prior authorization process. When conditions are met, we will authorize the coverage of Enbrel (Medicaid).

Drug Name (select from list of drugs shown / provide drug information)		
ENBREL 25 MG KIT	ENBREL 50 MG/ML SYRINGE	ENBREL 50 MG/ML SURECLICK SYR
ENBREL 25 MG/0.5 ML SYRINGE	ENBREL 50 MG/ML MINI CARTRIDGE	OTHER:_____

Patient Information	
Patient Name:	
Patient ID:	
Patient DOB:	

Prescribing Physician	
Physician Name:	
Physician Phone:	
Physician Fax:	
Physician Address:	
City, State, Zip:	

Diagnosis:	ICD Code:
Directions for administration:	

*****Please include all relevant clinical notes, lab work, medication history and any other applicable documentation.**

Please circle the appropriate answer for each question.

1. Is the requested drug required per court order? (court order required) Y N
   If the answer to this question is yes, approved for 365 days.
   If the answer to this question is no, go to question 2.

2. Does the patient have a diagnosis of ankylosing spondylitis (AS), psoriatic arthritis (PsA), and/or rheumatoid arthritis (RA), in the last 730 days? Y N
   If the answer to this question is yes, go to question 5.
   If the answer to this question is no, go to question 3.

3. Does the patient have a diagnosis of plaque psoriasis (PS) in the last 730 days? Y N
   If the answer to this question is yes, go to question 6.
   If the answer to this question is no, go to question 4.

4. Does the patient have a diagnosis of polyarticular juvenile idiopathic arthritis (PJIA) Y N

in the last 730 days?
If the answer to this question is yes, go to question 7.
If the answer to this question is no, denied.

5. Is the patient greater than or equal to 18 years of age? Y N
If the answer to this question is yes, go to question 8.
If the answer to this question is no, denied.

6. Is the patient greater than or equal to 4 years of age? Y N
If the answer to this question is yes, go to question 8.
If the answer to this question is no, denied.

7. Is the patient greater than or equal to 2 years of age? Y N
If the answer to this question is yes, go to question 8.
If the answer to this question is no, denied.

8. Does the patient have a history of heart failure in the last 365 days? Y N
If the answer to this question is yes, denied.
If the answer to this question is no, go to question 9.

9. Does the patient have a history of demyelinating disease (multiple sclerosis, optic neuritis and/or Guillain-Barre syndrome) in the last 365 days? Y N
If the answer to this question is yes, denied.
If the answer to this question is no, go to question 10.

10. Does the patient have a history of hematologic abnormalities in the last 180 days? Y N
If the answer to this question is yes, denied.
If the answer to this question is no, go to question 11.

11. Does the patient have a serious active infection (including Hepatitis B virus and/or tuberculosis) in the last 180 days? Y N
If the answer to this question is yes, denied.
If the answer to this question is no, go to question 12.

12. Does the patient have 1 claim for a contraindicated drug in the last 30 days ? Y N

Contraindicated Drugs

CYCLOPHOSPHAMIDE 25 MG CAPSULE
CYCLOPHOSPHAMIDE 50 MG CAPSULE
KINERET 100 MG/0.67 ML SYRINGE
ORENCIA 125 MG/ML SYRINGE

If the answer to this question is yes, denied.
If the answer to this question is no, go to question 13.

13. Is this request for a non-preferred drug? Y N
If the answer to this question is yes, go to question 14.
If the answer to this question is no, approved for 365 days.

14. Has the patient failed a 30-day treatment trial with at least 1 preferred agent within the last 180 days? Y N
If the answer to this question is yes, approved for 365 days.
If the answer to this question is no, go to question 15.

15. Is there a documented allergy or contraindication to preferred agents in this class? Y N
If the answer to this question is yes, approved for 365 days.
If the answer to this question is no, go to question 16.

16. Is the drug necessary for treatment of stage-4 advanced metastatic cancer and associated conditions? Y N

If the answer to this question is yes, approved for 365 days.
If the answer to this question is no, denied.

Comments:

I affirm that the information given on this form is true and accurate as of this date.

_____ _____

Prescriber (or Authorized) Signature Date